JP2016534084A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534084A5
JP2016534084A5 JP2016526034A JP2016526034A JP2016534084A5 JP 2016534084 A5 JP2016534084 A5 JP 2016534084A5 JP 2016526034 A JP2016526034 A JP 2016526034A JP 2016526034 A JP2016526034 A JP 2016526034A JP 2016534084 A5 JP2016534084 A5 JP 2016534084A5
Authority
JP
Japan
Prior art keywords
cells
compound
group
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016526034A
Other languages
English (en)
Japanese (ja)
Other versions
JP6389884B2 (ja
JP2016534084A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061418 external-priority patent/WO2015061229A1/en
Publication of JP2016534084A publication Critical patent/JP2016534084A/ja
Publication of JP2016534084A5 publication Critical patent/JP2016534084A5/ja
Application granted granted Critical
Publication of JP6389884B2 publication Critical patent/JP6389884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016526034A 2013-10-24 2014-10-20 癌を治療するための方法及び組成物 Active JP6389884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895308P 2013-10-24 2013-10-24
US61/895,308 2013-10-24
PCT/US2014/061418 WO2015061229A1 (en) 2013-10-24 2014-10-20 Methods and compositions for treating cancer

Publications (3)

Publication Number Publication Date
JP2016534084A JP2016534084A (ja) 2016-11-04
JP2016534084A5 true JP2016534084A5 (show.php) 2017-11-16
JP6389884B2 JP6389884B2 (ja) 2018-09-12

Family

ID=52993423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526034A Active JP6389884B2 (ja) 2013-10-24 2014-10-20 癌を治療するための方法及び組成物

Country Status (11)

Country Link
US (2) US9511050B2 (show.php)
EP (1) EP3060207A4 (show.php)
JP (1) JP6389884B2 (show.php)
KR (1) KR20160065986A (show.php)
CN (1) CN105848654B (show.php)
AU (1) AU2014340398A1 (show.php)
CA (1) CA2927148A1 (show.php)
IL (1) IL245281A0 (show.php)
MX (1) MX2016004678A (show.php)
RU (1) RU2016114498A (show.php)
WO (1) WO2015061229A1 (show.php)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
ME03010B (me) 2008-10-22 2018-10-20 Array Biopharma Inc Jedinjenja supstituisanog pirazol0[1,5-]pirimidina као inhibitori trk kinaze
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL2918588T3 (pl) 2010-05-20 2017-10-31 Array Biopharma Inc Związki makrocykliczne jako inhibitory kinazy TRK
CN107011242B (zh) 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
WO2015061229A1 (en) * 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer
JP6654197B2 (ja) 2014-10-09 2020-02-26 オンターナル セラピューティック インコーポレイテッドOncternal Therapeutics, Inc. インドリノン化合物及びその使用
TWI767858B (zh) 2014-11-16 2022-06-11 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
KR102277538B1 (ko) * 2015-06-08 2021-07-14 주식회사 대웅제약 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
DK3436434T3 (da) 2016-03-31 2020-09-21 Oncternal Therapeutics Inc Indolin-analoger og anvendelser deraf
DK3439662T3 (da) 2016-04-04 2024-09-02 Loxo Oncology Inc Væskeformige formuleringer af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazol[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3458456B1 (en) 2016-05-18 2020-11-25 Loxo Oncology Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10613088B2 (en) * 2016-06-12 2020-04-07 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
US10761081B2 (en) * 2016-06-12 2020-09-01 Mohammad Abdolahad Method and system for metastasis diagnosis and prognosis
CN109789127B (zh) 2016-07-29 2022-03-25 英克特诺治疗公司 吲哚啉酮化合物的用途
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
KR102747156B1 (ko) * 2017-02-28 2024-12-26 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 전립선 암의 검출
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110845389A (zh) * 2019-10-17 2020-02-28 袁健 一种新型i型拓扑异构酶抑制剂
CN114057626B (zh) * 2021-12-07 2023-06-30 山东第一医科大学(山东省医学科学院) 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物
WO2026009227A1 (en) 2024-07-04 2026-01-08 Yeda Research And Development Co. Ltd. Compositions for downregulating zeb2 in macrophages and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3483704D1 (de) 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
JP2002531498A (ja) 1998-12-04 2002-09-24 ニューロサーチ、アクティーゼルスカブ イオンチャネル活性剤としてのイサチン誘導体の使用方法
CN1155572C (zh) 2001-01-19 2004-06-30 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US20030157486A1 (en) 2001-06-21 2003-08-21 Graff Jonathan M. Methods to identify signal sequences
WO2006073458A2 (en) 2004-04-30 2006-07-13 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a c5-modified pyrimidine
WO2006117414A1 (es) 2005-04-29 2006-11-09 Proyecto De Biomedicina Cima, S.L. Modelo animal no humano de sarcoma
WO2008083326A2 (en) * 2006-12-29 2008-07-10 Georgetown University Targeting of ews-fli1 as anti-tumor therapy
US8232310B2 (en) 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
SI2154966T1 (sl) 2007-04-20 2014-02-28 The Research Foundation Of State University Of New York Benzimidazoli in njihovi farmacevtski sestavki
WO2013151981A1 (en) * 2012-04-02 2013-10-10 Gradalis, Inc. Ewing's sarcoma bifunctional shrna design
CN107011242B (zh) 2012-04-12 2020-08-07 乔治城大学 用于治疗尤文肉瘤家族肿瘤的方法和组合物
WO2015061229A1 (en) * 2013-10-24 2015-04-30 Georgetown University Methods and compositions for treating cancer

Similar Documents

Publication Publication Date Title
JP2016534084A5 (show.php)
ES2690341T3 (es) Derivados de 2-amino-5-trifluorometil-pirimidina y su uso como inhibidores de la quinasa PTK2
JP2016503797A5 (show.php)
JP2015143283A5 (show.php)
JP2015511638A5 (show.php)
JP2017538689A5 (show.php)
JP2019513770A5 (show.php)
IL278297B2 (en) Substituted heterocyclic inhibitors of ptpn11
JP2016526540A5 (show.php)
JP2017527532A5 (show.php)
JP2017511360A5 (show.php)
JP2019512535A5 (show.php)
JP2017537940A5 (show.php)
JP2017531648A5 (show.php)
JP2015532295A5 (show.php)
JP2017510610A5 (show.php)
JP2020506205A5 (show.php)
JP2015508103A5 (show.php)
JP2016505637A5 (show.php)
JP2017533930A5 (show.php)
JP2021512055A5 (show.php)
RU2019142472A (ru) Глюкуронидные пролекарства ингибиторов янус-киназы
JP2015528814A5 (show.php)
RU2014145285A (ru) Ингибиторы протеинкиназ
JP2016525104A5 (show.php)